Company
4D Molecular Therapeutics, Inc. (FDMT)
Standardized SEC financial data for 4D Molecular Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001650648 · NASDAQ · Biological Products, (No Diagnostic Substances).
Operating margin
-187.2%
Net margin
-164.4%
Revenue growth (YoY)
230194.6%
Return on equity
-27.7%
Free cash flow
-$109.6M
Current ratio
9.39×
EPS (diluted)
$-2.42
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $13.6M | $18.0M | $3.1M | $20.7M | $37K | $85.2M |
| R&D expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $276.7M | $153.0M | $52.4M | $249.1M | $149.3M | $514.0M |
| Total current assets |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$50.9M | -$69.1M | -$86.7M | -$75.8M | -$134.6M | -$109.1M |
| Capital expenditures |
Get FDMT data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/FDMT/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/FDMT/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"